Solantey
Post# of 30066
Posted On: 08/02/2014 3:22:53 PM
The post below from Ihub was excellent. No bashing, no pumping and very well written with no "just sayin'" or citing $AMBS Twitter followers.
I would welcome these type of posts from you anytime. Well done. If this is representative of who you really are versus the plethora of aliases and personas, then I hope to read more.
Bravo.
Solantey Member Level Saturday, 08/02/14 11:47:23 AM
Re: Riskreturn168 post# 106773
Post # of 106818
I don't equate challenging Gerald's character with challenging his judgement.
I think Gerald's character is fine. I think his judgement relative to being the C.E.O. of AMBS has at times created challenging situations for the shareholders. Based on what he's accomplished to date I'd give him a grade of B+.
You probaly recall earlier in the year when right after stating that the company had found a cusip number under which it could bill the cost of a LymPro test that he then added there would be no near term partnership for LymPro. No reason to state it. Share price tanked from .14 to .06 as I recall. He released a blog the next day and a filing that indicated he'd purchase a few shares.
Leading into the A.A.I.C. I think the shareholders/market were led to believe that the LymPro data would be released there. Major world stage for Alzheimer's. It didn't happen and the share price took a hit. There were those that said that Gerald had decided to wait to release the data at the C4CT Summit as it would be in the U.S. with the focus on AMBS and LymPro.
Then it's announced the day before the C4CT Summit that only partial LymPro data would be released. This drew attention to the small sample size and the fact that the data analysis was done "in-house" and the only number released was an 80% detection rate.
Evidently Gerald e-mailed some individuals that the data would be good. One poster termed it "epic".
Gerald "tweeted" yesterday that he would post a blog next week and also that LymPro could be "tweaked" to improve it.
I think Gerald's character is just fine. Also other than the first incident I don't know to what extent the manner in which they were handled was Gerald's decision. He does have a management support team, a board of directors, and a scientific advisory board to offer their input.
Obviously LymPro is the key to where the stock price is headed over the next three months as it is the one asset that could generate revenue short term from a marketing partnership.
The heavy volume over the last three days indicates that the "big boys" are currently in control of the stock and that the retail investor is along for the ride. The one thing that I do know for certain is that I have no idea where the share price is headed.
Note: Did anyone take the time to view the available webcast of the C4CT Summit? I counted about twelve individuals in the audience. Also did anyone notice that Cavendish Global's logo wasn't on the list of supporters?
I would welcome these type of posts from you anytime. Well done. If this is representative of who you really are versus the plethora of aliases and personas, then I hope to read more.
Bravo.
Solantey Member Level Saturday, 08/02/14 11:47:23 AM
Re: Riskreturn168 post# 106773
Post # of 106818
I don't equate challenging Gerald's character with challenging his judgement.
I think Gerald's character is fine. I think his judgement relative to being the C.E.O. of AMBS has at times created challenging situations for the shareholders. Based on what he's accomplished to date I'd give him a grade of B+.
You probaly recall earlier in the year when right after stating that the company had found a cusip number under which it could bill the cost of a LymPro test that he then added there would be no near term partnership for LymPro. No reason to state it. Share price tanked from .14 to .06 as I recall. He released a blog the next day and a filing that indicated he'd purchase a few shares.
Leading into the A.A.I.C. I think the shareholders/market were led to believe that the LymPro data would be released there. Major world stage for Alzheimer's. It didn't happen and the share price took a hit. There were those that said that Gerald had decided to wait to release the data at the C4CT Summit as it would be in the U.S. with the focus on AMBS and LymPro.
Then it's announced the day before the C4CT Summit that only partial LymPro data would be released. This drew attention to the small sample size and the fact that the data analysis was done "in-house" and the only number released was an 80% detection rate.
Evidently Gerald e-mailed some individuals that the data would be good. One poster termed it "epic".
Gerald "tweeted" yesterday that he would post a blog next week and also that LymPro could be "tweaked" to improve it.
I think Gerald's character is just fine. Also other than the first incident I don't know to what extent the manner in which they were handled was Gerald's decision. He does have a management support team, a board of directors, and a scientific advisory board to offer their input.
Obviously LymPro is the key to where the stock price is headed over the next three months as it is the one asset that could generate revenue short term from a marketing partnership.
The heavy volume over the last three days indicates that the "big boys" are currently in control of the stock and that the retail investor is along for the ride. The one thing that I do know for certain is that I have no idea where the share price is headed.
Note: Did anyone take the time to view the available webcast of the C4CT Summit? I counted about twelve individuals in the audience. Also did anyone notice that Cavendish Global's logo wasn't on the list of supporters?
(0)
(0)